While belzutifan’s FDA approval includes treatment for “advanced RCC,” its mechanism of action specifically targets the VHL-HIF-2α pathway characteristic of ccRCC, and clinical trials have primarily enrolled patients with clear cell histology (52). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.